Abstract:This study aimed to explore the historical research progress on benign prostatic hyperplasia from the perspective of traditional Chinese medicine theory and the treatment of benign prostatic hyperplasia (BPH) with Qian Lie Xing Fang (QLXF) via the warming and tonifying of kidney yang, promotion of blood circulation, and clearing of meridians. First, network pharmacology analysis was used to screen and identify possible pathways for BPH treatment with QLXF. Subsequently, molecular docking analysis helped explore the mechanism of action by which the components of QLXF affected androgen receptor (AR) and type 5 phosphodiesterase inhibitor (PDE-5) levels. Targets for treatment with QLXF were identified from the online Mendelian inheritance in man and DisGeNET databases. BPH-related genes were identified using GeneCards and online Mendelian inheritance in man databases, and their intersection was used to construct a protein-protein interaction network analysis graph. Subsequently, gene ontology and Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analyses were performed. The semiflexible docking of the ingredients of QLXF acting on the 2 targets was performed via molecular docking and molecular dynamics simulation, to elucidate the mechanism of action by which the active ingredients affect AR and PDE-5 levels further. This enabled us to explore the pattern of interactions between small active ingredient molecules, the target protein, and the stability after binding at the microscopic level. Gene ontology enrichment analysis showed that QLXF affected several processes, such as DNA transcription factor binding, kinase binding, protein homodimerization activity, protein structure domain-specific binding, and protein-coupled amine receptor activity in BPH patients. KEGG results showed that chemical carcinogenic reactive oxidative species and the JAK-STAT, Pl3k-Akt, FoxO, NF-κB, and other pathways were significantly enriched. Conducting molecular docking studies to investigate the interaction of active components from QLXF with AR and PDE-5, it was found that MOL002260 may possess the potential to inhibit PDE-5 activity, while MOL010578 may exhibit the capability to inhibit AR activity. QLXF is closely associated with various biological processes and KEGG signaling pathways related to BPH. The active ingredients of QLXF were investigated for their interactions with AR and PDE-5, with a primary focus on the small molecules MOL002260 and MOL010578.

[Influence of Qianlie Antong Tablets on Expresstion of VEGF and Bfgf in Protatic Tissues of BHP Rats].

[Therapeutic effect of Lingze Tablets on benign prostatic hyperplasia in rats: An exploration based on the VEGFA/TNF/IL-6 signaling pathway]

Effect of Bushenhuoxue Decoction on the Expression of VEGF and bFGF in the Tissue of Model Rats with Benign Prostatic Hyperplasia

Exploring the Efficacy of the Traditional Chinese Medicine Compound Formulas Qianlong Shutong Formula in the Treatment of Benign Prostatic Hyperplasia

Computer Prediction and Experimental Verification of Guizhi Fuling Pill in the Treatment of Benign Prostatic Hyperplasia

Exploring the mechanism of action of Qian Lie Xing Fang during the treatment of benign prostatic hyperplasia via network pharmacology and molecular dynamics simulation analyses

Anti-proliferative effects of qianliening capsules on prostatic hyperplasia in vitro and in vivo

Effect of epristeride on the expression of IGF-1 and TGF-β receptors in androgen-induced castrated rat prostate

Anti-inflammatory Effect and Prostate Gene Expression Profiling of Steryl Ferulate on Experimental Rats with Non-Bacterial Prostatitis

Protective effect of bamboo shoot oil on experimental nonbacterial prostatitis in rats

[Action mechanisms of Qianlie Jindan Tablets on chronic nonbcterial prostatitis in rats: An exploration based on non-targeted urine metabolomics]

A preliminary study on the efficacy and mechanism of Chinese traditional medicine Zeguilongshuang capsule for the treatment of benign prostatic hyperplasia

[Effects of Testosterone on GDNF Mrna Expression in Rat Ventral Prostate].

Qianliening capsule treats benign prostatic hyperplasia via suppression of the EGF/STAT3 signaling pathway

Bushen Tongluo formula ameliorated testosterone propionate-induced benign prostatic hyperplasia in rats

Zhuangyao Jianshen pill ameliorates testosterone-induced benign postatic hyperplasia in rats

Shuangshi Tonglin Capsule treats benign prostatic hyperplasia through the ROS/NLRP3 signaling pathway

The Endothelial Function Study of Benign Prostatic Hyperplasia

Changes of rat's benign hyperplasia prostate glandular epithelium cells after interfering cholinergic innervations by drug

Effects of Qufengtongluo Recipe on Α-Sma in Rats with Mesangial Proliferative Glomerulonephritis

Changes in the Expression and Functional Activities of C-X-C Motif Chemokine Ligand 13 (CXCL13) in Hyperplastic Prostate